| Followers | 24 |
| Posts | 1403 |
| Boards Moderated | 0 |
| Alias Born | 01/27/2021 |
Wednesday, March 24, 2021 2:43:45 PM
I've said this before, but I'm a huge fan of HK and Marjac's work and I think the Rule 60 motion is a worthy and inspiring quest that will make Judge Du rethink some things even if she ultimately rejects it on some procedural grounds. As I'm not a lawyer, I don't know what those procedural grounds would be, but I imagine Hikma and Dr. Reddys will try to get this booted on those grounds simply because they know the danger of letting the judge recalculate her original findings on the facts of the case. As I wrote in the last hour, the greatest accomplishment of the Rule 60 motion might be to have led Judge Du to rethink some things on the remote chance that the Supreme Court takes up the case and kicks it back to her with instructions to weigh the secondary considerations differently.
I haven't read the Judge Du ruling since last year, but I do recall being left with the impression that Judge Du thought the whole thing was a pretty close call. That's why I was surprised when the Federal Circuit dismissed the appeal without seemingly much thought. The Federal Circuit judges seemed to be saying that the issues Judge Du decided were discretionary and subjective and it wasn't really their place to second-guess her because she made the rulings after sitting through a long trial, watching the demeanor of the witnesses as they spoke and reviewing all the evidence.
As to hitting the bong, the words did bring back some memories of some very happy college days so thanks for that.
I haven't read the Judge Du ruling since last year, but I do recall being left with the impression that Judge Du thought the whole thing was a pretty close call. That's why I was surprised when the Federal Circuit dismissed the appeal without seemingly much thought. The Federal Circuit judges seemed to be saying that the issues Judge Du decided were discretionary and subjective and it wasn't really their place to second-guess her because she made the rulings after sitting through a long trial, watching the demeanor of the witnesses as they spoke and reviewing all the evidence.
As to hitting the bong, the words did bring back some memories of some very happy college days so thanks for that.
Recent AMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
